Showing 121-130 of 1560 results for "".
Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma
https://reachmd.com/programs/medical-industry-feature/biomarker-predicts-response-to-bcma-car-t-cell-therapy-in-multiple-myeloma/29919/Discover how measuring ALC after CAR T-cell therapy injection for multiple myeloma can help predict a patient response and improve treatment planning.Seizures & Epilepsy: How Cell Phone Videos Could be an Effective Tool
https://reachmd.com/programs/neurofrontiers/seizures-epilepsy-how-cell-phone-videos-could-be-an-effective-tool/14999/What role do cell phone videos have in diagnosing patients with epilepsy? And how could they help non-medically trained witnesses?The Possibility of Cardiac Cell Regeneration
https://reachmd.com/programs/heart-matters/the-possibility-of-cardiac-cell-regeneration/4742/A growing body of evidence tells us human cardiomyocytes are capable of endogenous regeneration. The concept has been debated in medicine for some time, but as more data accumulate behind this theory, it is very tempting to think about novel treatment strategies. Dr. Stefan Jovinge, director of theEmerging Frontiers: CAR T-Cell Therapy for Solid Tumors in Thyroid Cancer
https://reachmd.com/programs/project-oncology/emerging-frontiers-car-t-cell-therapy-for-solid-tumors-in-thyroid-cancer/26527/Join us as we dive into recent research investigating CAR T-cell therapy’s emerging role for solid tumors in thyroid cancer.Epithelial Cell Activation in Sjögren’s: A New Target in Chronic Inflammation
https://reachmd.com/programs/living-rheum/epithelial-cell-activation-in-sjogrens-a-new-target-in-chronic-inflammation/36341/New research into primary Sjögren’s disease reveals how epithelial cells may actively drive chronic inflammation through gene-level changes. In this AudioAbstract, Ryan Quigley walks through the findings from an in vitro study examining the effects of prolonged interferon gamma exposure on salivarySickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
https://reachmd.com/programs/project-oncology/sickle-cell-disease-care-examining-hydroxyurea-and-chronic-transfusions/36449/Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. However, considerations remain, including their impact on cardiac health. Learn about these long-standing therapies and best practicesAdvances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
https://reachmd.com/programs/project-oncology/advances-in-disease-modifying-and-curative-therapies-for-sickle-cell-disease/35928/Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated with the disease, they do not correct or fix them, which is why curative strategiesFDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
https://reachmd.com/programs/project-oncology/fda-disco-two-approvals-alk-positive-non-small-cell-lung-cancer/9775/FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.Reimagining Autoimmune Care with CAR-Based Cell Therapies
https://reachmd.com/programs/living-rheum/reimagining-autoimmune-care-with-car-based-cell-therapies/32815/Tissue-Engineered Trachea Transplantation
https://reachmd.com/programs/focus-on-future-medicine-and-genetics/tissue-engineered-trachea-transplantation/4105/Recently, scientists were able to engineer for the first time a trachea developed from a patient's own stem cells, wherein a donor's trachea was lined with the patient's stem cells to prevent transplant rejection. Immunosuppressive therapy was not necessary, and the patient remains in good condition